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A yearling quarter horse, which was raised in southern California, received routine vaccinations for pre-
vention of infection by Eastern equine encephalomyelitis virus (EEEV). One week later, severe neurologic
signs developed, and the horse was humanely destroyed because vaccine-related encephalomyelitis was
suspected. A final diagnosis of EEEV infection was established on the basis of acute onset of the neuro-
logic signs, histopathologic and serologic testing, and isolation and molecular characterization of EEEV
from brain tissue. The vaccine was extensively tested for viral inactivation. Nucleotide sequences from the
vaccine and the virus isolated in the affected horse were also compared. In California, arboviral encepha-
lomyelitides are rarely reported, and EEEV infection has not previously been documented. This report
describes the occurrence of EEEV infection in the horse and the investigation to determine the source of
infection, which was not definitively identified.
astern equine encephalomyelitis virus (EEEV) is a mos-
quito-borne virus in the family Togaviridae, genus
Alphavirus. EEEV, Western equine encephalomyelitis virus
(WEEV), and Venezuelan equine encephalomyelitis virus
(VEEV) are related but genetically distinct alphaviruses.
EEEV and VEEV are lethal in up to 90% of recognized equine
cases, whereas WEEV is least virulent in horses, which have a
mortality rate of approximately 40% (1). EEEV may also
cause fatal encephalitis in humans (mortality rate 50%-75%)
(2). In the United States, enzootic EEEV occurs mainly from
New England to Florida and along the Gulf Coast, with rare
reports of foci as far inland as Michigan and South Dakota (3).
In North America, sylvatic populations and the mosquito
Culiseta melanura maintain the virus in hardwood, salt-water
swamp habitats. Large populations of this mosquito allow
amplification of the virus by transmission among wild birds
(4). In wild birds indigenous to North America, the infection is
usually innocuous, whereas in pheasants, cranes, and emus,
the disease is often lethal. C. melanura feeds almost exclu-
sively on passerine birds; however, spillover of EEEV from
the enzootic vector into several other mosquito species (e.g.,
Aedes spp.), which feed on tangential hosts such as humans
and equines, may result in large epizootics with high mortal-
ity rates (4-6). Our paper describes a sporadic case of EEEV
infection in a horse outside the known geographic range of
this virus and the ensuing investigation to determine the
source of exposure.
Materials and Methods 
Case Report
In April 2000, a 14-month-old gelding quarter horse was
seen at a veterinary referral hospital in southern California for
sudden onset of quadraparesis and recumbency. The horse had
no history of prior neurologic disease. He had been castrated
approximately 90 days before the illness without complication.
A multidose, multivalent vaccine containing formalin-inacti-
vated EEEV and WEEV, influenza virus, and tetanus toxoid
was administered to the affected horse and 27 stable mates 1
week before the onset of illness.
The horse appeared alert and healthy the night before onset
of clinical signs. At 6:30 a.m. on April 21, he was found down
in his stall and unresponsive to external stimuli. The referring
veterinarian found a recumbent, comatose horse with sponta-
neous nystagmus and flailing, incoordinated movements. Ini-
tial therapy included intravenous corticosteroids, fluid therapy
(including glucose to treat possible hyperkalemic periodic
paralysis), and diazepam for intermittent seizures. The horse
did not respond to therapy and was sent to the referral hospital. 
On examination at the hospital, the horse was comatose
with elevated heart and respiratory rates and a normal rectal
temperature. A neurologic exam showed that pupillary light
responses were absent bilaterally. Palpebral reflexes were
present although weak. No organized motor movements
occurred in response to stimuli. Initial emergency treatment
consisted of intravenous fluids with dimethyl sulfoxide and
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flunixin meglumine. Cervical and skull radiographs were per-
formed and were within normal limits. An atlanto-occipital
cerebrospinal fluid tap was also performed, and no abnormali-
ties were seen on gross observation. At this point, diffuse cor-
tical disease was evident. Trauma appeared very unlikely, and
an infectious process or toxicosis seemed more probable.
Because of the grave prognosis, the owners elected to eutha-
nize the horse. The carcass was sent to the Animal Health and
Food Safety Laboratory System, San Bernardino Branch,
School of Veterinary Medicine, University of California,
Davis, for necropsy.
Results
Pathology
Results of gross necropsy examination were unremarkable
except for markedly hemorrhagic bladder mucosa. Histologic
examination revealed lesions mainly confined to the cerebral
cortex, thalamus, hypothalamus, and anterior portion of the
spinal cord (C1-C4). Lesions in the brain were characterized by
a multifocal to diffuse neutrophilic response with gradual pro-
gression to mononuclear cell infiltrates in some areas. Vascular
damage and fibrin thrombi were evident (Figure 1). Some
blood vessels had swollen endothelium surrounded by a thick
layer of mononuclear cells. A mild degree of meningitis was
present, with pleocellular response containing mainly mono-
nuclear and neutrophilic infiltrates. The neuropil showed fine
vacuolation, indicating edema. Some axons were markedly
shrunken. The remaining portion of the spinal cord was unre-
markable. The urinary bladder had diffuse submucosal hemor-
rhages. The lung showed flooding of the alveoli with
eosinophilic fluid. The remaining tissues were unremarkable. 
Virology
Portions of brain tissue were collected and sent for rabies
testing at the local public health laboratory. Results were nega-
tive. Fresh, frozen brain tissues and serum were submitted to
the National Veterinary Services Laboratories (NVSL). Tests
for equine encephalomyelitides included virus isolation and
serology for WEEV, EEEV, VEEV, Equid herpesvirus 1
(EHV-1), and West Nile virus (WNV). For virus isolation, a
10% suspension of brain sample was prepared and injected
into flasks of RK13, equine dermal, and Vero-MARU cells
(Vero M). This cell line was obtained by NVSL at the 135th
passage level from the Middle America Research Unit
(MARU) as a multipurpose cell line for virus isolation in 1980
and has been maintained by the NVSL since that time. Addi-
tional brain suspension was injected intracerebrally into 16
suckling 4-day-old mice (from 2 litters). Cytopathic effects
were observed in the RK13 and Vero M cells at 2 days after
injection. Examination using electron microscopy of the RK13
cell culture fluids showed particles with morphologic features
compatible with alphaviruses. 
Virus preparations from both the cell culture supernatant
and suckling mouse brains of mice that died were identified as
EEEV by a complement fixation test with reference antisera.
In that test, virus reacted strongly with EEEV antiserum and
weakly or not at all with WEEV and VEEV antisera. 
Serum collected from the yearling horse on April 21 before
it died was tested for antibodies to EEEV, WEEV, and VEEV
by hemagglutination inhibition (HI) and plaque reduction neu-
tralization testing (PRNT). The serum had a HI titer of 20
against both EEEV and WEEV. HI antibodies to VEEV were
not detected. In the PRNT, the serum neutralizing antibody
titer versus EEEV was ≥ 100 but was undetectable against
either WEEV or VEEV. The serum was also positive in an
immunoglobulin (Ig) M-capture enzyme-linked immunosor-
bent assay for EEEV with a titer of ≥ 1000. Additional tests for
antibodies to equine herpesvirus 1 and WNV were negative. 
The Center for Vector-Borne Disease Research at the Uni-
versity of California, Davis (CVBDR), U.S. Army Medical
Research Institute of Infectious Diseases (USAMRIID), and
California Department of Health Services (CDHS) also
received homogenized brain suspension material. Isolation of
EEEV by mouse inoculation and cell culture supported
NVSL’s findings. The isolate was further characterized by
USAMRIID by reverse transcriptase-polymerase chain reac-
tion (RT-PCR) testing and sequencing as described (7,8), but
with primers listed in Table 1. A 1,165-nucleotide portion of
the viral genome including parts or all of the E2, 6K, and E1
genes was determined. Sequencing of the isolate showed an
18-nucleotide difference (98.5% homology) from the refer-
ence PE6 EEEV strain. Comparison with sequences that have
been submitted to GenBank indicated that the virus is a North
American antigenic variety in subtype 1 of the taxonomic
scheme recently proposed by Brault et al. (9).
Field Investigation 
Local, state, and federal agencies participated in a joint
field and laboratory investigation to determine the source of
infection. Four hypotheses were investigated to explain the
occurrence of EEEV outside its usual range: 1) imported
Figure 1. Photomicrograph of a section of the cerebral cortex from
horse with Eastern equine encephalomyelitis virus infection. Note the
dense neutrophilic response, vascular damage, and fibrin thrombi.
Hematoxylin and eosin stain.Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 285
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infection from an EEEV-endemic region, 2) autochthonous
transmission by locally infected mosquitoes, 3) intentional
inoculation of the horse with live EEEV by a person or by pur-
poseful contamination of the vaccine and 4) incomplete inacti-
vation of EEEV in a commercially inactivated viral vaccine.
Travel History 
We found no evidence that this case was due to importa-
tion from an EEEV-endemic region. The horse was born in
northern California and at 6 months of age was moved to
southern California for training. The horse traveled as far east
as Fort Worth, Texas, in July 1999 for showing purposes. The
rest of the 1999 horse show season took place in southern Cal-
ifornia. The horse was last moved to a new stable (Farm A) in
southern California during February 2000. He attended several
shows in this area and as far east as Hurricane, Utah. A review
of a list of participants at the horse shows recently attended
showed no horses from EEEV-endemic areas and no reports of
encephalomyelitis among other equine participants.
Surveillance for EEEV in Southern California
No evidence for autochthonous transmission of EEEV by
local mosquito populations was found through surveillance in
mosquitoes, sentinel chickens, wild birds, horses, and humans
from the region. California has an extensive, long-established
Arboviral Encephalitis Surveillance Program that is active
from April through October each year (10,11). The program
includes collection and testing of mosquito pools and sentinel
chicken flocks for WEEV and St. Louis encephalomyelitis
virus and surveillance for encephalomyelitis cases among
equids, ratites (e.g., emus, ostrich), and humans. Following
recognition of the equine EEEV case, CDHS began including
EEEV screening in its routine testing program.
Coincidentally, a sentinel chicken flock was located on
Farm A. Sera submitted from this flock in April were retro-
spectively tested for EEEV antibody by indirect immunoassay
and found to be negative. The flock remained seronegative for
EEEV from May through October. In addition, mosquitoes
were collected at Farm A and within a 5-mile radius with car-
bon dioxide traps. A total of 74 mosquitoes, including the
Culex spp. tarsalis, quinquefasciatus, erythrothorax, and stig-
matosoma, and Culiseta particeps, were collected in 23 trap
nights during May. Only 8 of 74 mosquito species were Culex
tarsalis, a known vector species of WEEV and a potential vec-
tor species of EEEV in California (12). Surveys for resting
adult mosquitoes in barns and other buildings yielded no mos-
quitoes. All mosquito pools were tested and found negative by
virus isolation in tissue culture. Routine biweekly testing of
sentinel chicken flocks and mosquito pools throughout Cali-
fornia until the end of October showed no further evidence of
EEEV activity in the state.
Despite enhanced surveillance, additional cases of EEV
infection in local animal and human populations were not
identified. Surveillance for encephalitis cases in horses and
humans was heightened in southern California after the equine
case was recognized. Veterinarians were alerted statewide
through a newsletter published by the California Department
of Food and Agriculture, and the local health department
issued a press release. Following the publicity, a veterinarian
reported three horses with acute neurologic disease during
mid-May at another ranch, Farm B, approximately 50 km from
Farm A. Necropsy and serologic testing of these cases per-
formed at the California Animal Health and Food Safety Labo-
ratory System, San Bernardino Branch, showed EHV-1 as the
likely cause of the outbreak at Farm B; no evidence of EEEV
infection was found. In addition, a brown-headed cowbird
(Molothrus ater) die-off at another horse ranch, Farm C,
approximately 80 km from Farm A, was investigated. No labo-
ratory evidence of EEEV infection was found in three dead
cowbirds collected from Farm C, although the causes of their
deaths were not determined.
No other horses at Farm A had encephalitis. To further
assess potential equine exposures at Farm A, a serosurvey of
10 randomly chosen stable mates of the affected horse were
tested for EEEV antibodies. The sample ranged in age from
weanlings to elderly horses; each had been vaccinated with the
multivalent vaccine against WEEV, EEEV, influenza viruses,
and tetanus (Vaccine A) from the same lot on the same day as
the case. These horses showed positive neutralizing antibody
titers by PRNT ranging from <20 to 320; none had IgM anti-
bodies to EEEV by an ELISA-capture test. Previous vaccina-
tion histories were not available for these horses or the case,
Table 1. Reverse transcriptase-polymerase chain reaction (RT-PCR) primers used to sequence Eastern equine encephalomyelitis virus RNA
Title Sense Primer Use Region
9930 Forward 5´-  GCGCTGCTTATTTTGCTGT  -3´ RT-PCR E1
11582 Reverse 5´- ATTATGCGCTGCCTGTAGTGTTTA -3´ RT-PCR E1
4043 Forward 5´- GTGCGCGGCGACATAACAAAGAG- 3´ RT-PCR NSP3
4976 Reverse 5´- CCGGGGGTACAGTGCCAGAGAA -3´ RT-PCR NSP3
10470 Forward 5´- ATGCCAAACTCATCATAGGTCCACT -3´ Sequencing E1
10938 Forward 5´- GTATAGCCACCGTTGCCTACAAATC -3´ Sequencing E1
11345 Forward 5´- CAGGCAGTGTATAAGGCTGTCTTAC -3´  Sequencing E1
T3 Forward 5´- AATTAACCCTCACTAAAGGGA -3´ Sequencing NSP3RESEARCH
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but the findings in the stable mates were compatible with
recent vaccination or the presence of maternal antibodies in
younger horses without natural exposure. 
Criminal Mischief
Although an intentional introduction of EEEV seemed
highly unlikely, recent concerns about bioterrorism made this
an important possibility to consider. We found no evidence of
purposeful contamination of the vaccine or intentional inocu-
lation of the horse. EEEV is not readily obtainable. Further-
more, no motive for such an act was found. 
Vaccine Studies
An extensive evaluation of the final hypothesis, residual
live EEEV in the vaccine, could not eliminate Vaccine A as the
source of infection. The farm manager ordered the multivalent
EEEV, WEEV, influenza viruses, and tetanus toxoid vaccine
by mail from an out-of-state vendor and stored the vials at 6° C
in a refrigerator at Farm A. The vaccine was a commercial,
four-way, multidose product that was administered intramus-
cularly by farm personnel. The viruses in the vaccine were for-
malin-inactivated, adjuvant-type, and of tissue-culture origin. 
Virus Isolation 
Three unused vials and one partially used vial of Vaccine
A were found in the refrigerator at Farm A. CDHS and
CVBDR attempted virus isolation by mouse inoculation and
cell culture by using the residual vaccine from Farm A. One-
day-old mice were inoculated by either intraperitoneal or
intracranial injections of the vaccine and were monitored for
18 days. Live EEEV was not isolated from any of the vials.
Additionally, the Center for Veterinary Biologics Laboratory
conducted safety tests on stored vaccine from the same lot as
Vaccine A, which was available because of licensing proce-
dures that require samples from each lot to be retained. Virus
isolation attempts on these samples were also negative by cell
culture and wet chick inoculations. 
Molecular Comparison of Horse and Vaccine Strains 
EEE viral RNA was extracted from the horse isolate and
passaged once via BHK (baby hamster kidney) cell culture at
CVBDR and directly from the residual vaccine and amplified
and sequenced in two separate regions of the genome accord-
ing to previously published protocols (7,8). The structural E1
region was amplified and compared with several other pub-
lished EEEV E1 sequences in GenBank; 1,100-nucleotide
sequences of the horse isolate and Vaccine A strain were com-
pared with each other as well as with the 10 most closely
matched published sequences in GenBank. The conclusions
from this laboratory’s study were very similar to the initial
gene sequencing of the horse isolate by USAMRIID. Table 2
illustrates a comparison of each GenBank sequence to the
sequence of the horse isolate. The phylogram is depicted in
Figure 2. 
The NSP3 (nonstructural) region was also amplified and
cloned to check for variability within Vaccine A and in the
horse viral isolate, as well as to compare with published EEEV
NSP3 sequences in GenBank. Four horse and five vaccine
viral RNA clones were sequenced and analyzed. Of the 508
nucleotides in each fragment, only one nucleotide difference
was evident among the cloned vaccine sequences, and only
one was found among the four sequences from horse isolates.
These differences could be a result of taq polymerase errors.
The consensus sequences for both the vaccine and the horse
EEEVl RNAs were compared with each other and with the
only two EEEV GenBank sequences that came up in a BLAST
search (Table 3, Figure 3).
Table 2. Comparisons of 1,100 nucleotide sequences of the horse 
virus isolate, Vaccine A virus strain, and selected GenBank isolates of 
the structural unit E1
GenBank accession no. Strain/isolate Mutations % Match
Horse 0 100
Vaccine 5 99.5
AF159551 LA50 7 99.4
L37662 PE6 vaccine 11 98.9
U01552 Decuir 13 98.5
U01558 Tenbroeck 15 98.6
U01554 NJ/60 15 98.6
AF159556 FL96-14834 17 98.5
X63135 ssp. N. Am. Variant 18 98.4
AF159550 MA38-Mass 19 98.3
U01555 ME771332 19 98.2
U01034 82V2137 19 98.3
Figure 2. Phylogram based on
nucleotide comparison from the E1
region of a horse infected with
Eastern equine encephalomyelitis
virus.Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 287
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Discussion
The identification of EEEV in a horse in California was
unprecedented and clearly represented a potential human and
animal health threat. In other areas of the country, equine epi-
zootics have been recognized as precursors to human disease
(13,14). The rapid recognition and reporting of the case per-
mitted an extensive investigation into the source of exposure.
 Several factors must be met to sustain epidemics, includ-
ing virulent viruses, adequate vectors, neighboring intermedi-
ate hosts, and populations of susceptible horses and people
(5,15). Such isolated cases as the one mentioned are sure to
increase veterinary attention to the possibility of neurologic
patients having EEEV infections, as well as elevating public
awareness of the disease and methods of prophylaxis.
A diagnosis of EEEV infection was made on the basis of
the rapid clinical onset of neurologic signs, compatible histo-
pathologic and serologic findings, and isolation and molecular
characterization of EEEV from brain tissue. Several neuro-
logic conditions were considered in the differential diagnosis,
including other viral encephalomyelitides (rabies, Aujesky dis-
ease, Borna disease, EHV-1 myeloencephalopathy, WEEV,
and WNV encephalomyelitis), bacterial meningitis, listeriosis,
leukoencephalomalacia, lead poisoning, equine protozoal
myeloencephalitis, nigropallidal encephalomalacia, botulism,
and verminous encephalitis. 
California’s Arboviral Encephalitis Surveillance Program
is among the most comprehensive in the United States. The
jurisdiction where the horse was stabled participated in the
program, and a sentinel chicken flock was located adjacent to
the farm. In this case, locally infected mosquitoes were appar-
ently not the source of exposure. Furthermore, there was no
evidence of spread from the infected horse to the local mos-
quito populations based on mosquito pool and sentinel chicken
flock testing throughout the year. The likelihood of EEEV’s
having become established in California following this iso-
lated equine case is remote but still important to monitor
because of the public health implications. First, the primary
vector of EEEV in North America, C. melanura, is not known
to occur in California (16). In addition, our equine case was
diagnosed in April, when mosquito populations are low in
southern California; particularly the vector species known to
feed on both birds and horses. Second, this case had a rapid
clinical course, with euthanasia in <24 hours after onset of
clinical signs. Since horses are known to have a short viremia
(1 to 3 days’ duration) it is unlikely that any mosquitoes
acquired the infection from the horse during this short time
period. However, if vector abundance were increased, this
horse would have had the potential to amplify the virus (5).
Incidental infections could have occurred among barn person-
nel and susceptible horses at Farm A and nearby locations by
transmission from mosquitoes that acquired the infection from
the case. Of even greater concern, competent vectors could
then spread the disease further by feeding on susceptible wild
bird populations, potentially establishing an enzootic cycle in
southern California.
After we excluded disease by natural infection, bioterror-
ism, and importation, incomplete formalin inactivation of the
EEEV in the vaccine had to be considered a likely possibility.
Previous reports of residual virus in formalin-inactivated vac-
cines exist. Documented outbreaks due to Poliovirus  (PV),
Foot-and-mouth disease virus, and VEEV have been directly
related to the use of formalin-inactivated vaccines (17-19).
Attempts to isolate live EEEV from residual and stored vac-
cine were unsuccessful. However, this does not eliminate the
possibility that the horse received live virus with its immuniza-
tion. If inactivated viruses existed in the vaccine, they were
likely present in undetectable levels during vaccine develop-
ment and testing. Additionally, the live viruses were probably
distributed sporadically throughout the vaccine lot, allowing
for only an isolated recognized case. The situation could also
be analogous to the 1955 “Cutter inactivated poliovirus inci-
dent,” when children became infected with PV after vaccina-
tion and follow-up investigation disclosed that several lots of
Salk PV vaccine contained live PV, despite being produced
with formalin inactivation in full compliance with federal reg-
ulations (19). In the PV vaccine example, live virus was not
uniformly distributed in that vaccine lot (20). 
We further explored the hypothesis of residual live virus in
the vaccine through molecular epidemiologic studies. Similar
studies were used to examine the role of the VEEV vaccine in
the 1967-1972 VEEV pandemic in Central America (21).
Unfortunately, the North American variety of EEEV is the
most genetically homologous of the alphaviruses and therefore
the least conducive to molecular comparison of strains (9,22).
In our study, the greatest nucleotide homology in the E1 region
was among the horse virus isolate, Vaccine A virus, and the
Table 3. Comparisons of 508 nucleotide sequences of the horse virus 
isolate, Vaccine A virus strain, and selected GenBank isolates of the 
nonstructural unit NSP3
GenBank 
accession no. Strain/isolate Mutations %  Match
Horse 0 100
Vaccine 0 100
X63135 ssp. N. Am. Variant 5 99.0
U01034 82V2137 5 99.0
Figure 3. Phlyogram based on nucleotide comparison from the NPS3 (nonstructural) region of a horse infected with Eastern equine encephalomy-
elitis virus.RESEARCH
288 Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002
LA50 virus strain (Figure 2). Differences among sequences
from Vaccine A EEEV and the horse viral isolate in the E1
region might represent mutations that occurred when virus
passed through various hosts (horse brain/BHK cell culture/1)
or genetic variants within the vaccine strain. However, we con-
cluded on the basis of the limited number of clones analyzed
that there were few to no other EEEV subclones in the horse
viral isolate or vaccine virus. The NSP3 region proved to be
more highly conserved and therefore less conclusive. Also,
very few EEEV sequences that included the nonstructural
regions have been published in GenBank, so comparison was
limited. Regardless, the Vaccine A EEEV appears to be closely
related to the horse viral isolate; thus, the possibility of live
virus in the formalin-treated vaccine infecting the horse
remains.
We are unaware of any reports of problems with this vac-
cine lot, despite notification of the manufacturer and other
state veterinarians. If Vaccine A or portions of the lot con-
tained live virus, many exposed horses may not have been sus-
ceptible because of previous immunization or presence of
maternal antibodies. In addition, cases may have been unrec-
ognized or unreported. If Vaccine A was the source of infec-
tion for this case or other cases, it was probably a rare event. 
A definitive source of infection may never be revealed in
this case. However, the case illustrates the need to maintain
awareness that EEEV can occur outside its normal geographic
boundaries; it also underscores the importance of prompt diag-
nosis, reporting, and surveillance for arboviral encephalomy-
elitides. 
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